A new study examines pregnancy outcomes among women using stimulants or atomoxetine during pregnancy, finding modest increases in some complications with stimulant use while highlighting important limitations of observational data.
A large claims-based study found no increased risk for most outcomes with first-trimester stimulant exposure during pregnancy, but higher risks when use continued later in pregnancy.
Based on this large cohort study including 990 pregnancies with first trimester exposure to atomoxetine, the researchers observed no increase in major congenital malformations overall and no statistically increased risk estimates for cardiac or limb malformations.
Modafinil (brand name Provigil) is a wake-promoting agent which is used to treat sleepiness due to narcolepsy, shift work sleep disorder, or obstructive sleep apnea. It is also used to in others settings, often [...]
